Market›Health Care›Pharmaceuticals›Pharmaceuticals
VIRPAX PHARMACEUTICA

VRPX

$0.01Apr 26, 2021 – Apr 24, 2026
Health CarePharmaceuticals$0M
MVM
+$0.0M

Every news event mapped to its market reaction — 90 events, 61 months of data. No predictions, just what happened.

PositiveNegativeNo data· Dot size = magnitude · Scroll to zoom · Drag to pan
Hover to inspect

Want the full written briefing?

The chart shows what moved — the briefing shows why. Sourced, dated, no hot takes.

Subscribe on Substack →

News Events

DateReturnCategorySourceHeadline
2024-07-08+100.5%newsSeeking AlphaVirpax announces $2.5M loan financing, additional pact with investor
2024-07-08+100.5%legalSEC EDGARVRPX 8-K: 1.01, 2.03, 5.01, 5.02, 7.01 (SEC Filing)
2024-05-14-76.0%earningsSeeking AlphaVirpax Pharmaceuticals GAAP EPS of -$2.75
2025-04-03-60.8%legalSEC EDGARVRPX 8-K: 3.01, 5.02 (SEC Filing)
2025-04-03-60.8%newsInvesting.comVirpax Pharmaceuticals to be delisted from Nasdaq - Investing.com
2025-04-03-60.8%newsInvesting.comVirpax Pharmaceuticals stock plummets on Nasdaq delisting news - Investing.com
2024-07-10+43.8%legalSEC EDGARVRPX 8-K: 8.01 and (SEC Filing)
2024-10-07-24.0%legalSEC EDGARVRPX 8-K: 3.01 and 5.02 (SEC Filing)
2025-03-19-24.0%newsSeeking AlphaVirpax Pharmaceuticals to conduct reverse stock split
2025-03-19-24.0%newsInvesting.comVirpax Pharmaceuticals announces 1-for-25 reverse stock split - Investing.com
2024-03-01+22.5%legalSEC EDGARVRPX 8-K: 1.01, 2.03, 3.03, 5.03, 8.01 (SEC Filing)
2024-11-22-21.5%legalSEC EDGARVRPX 8-K: 3.01, 5.02, 8.01 (SEC Filing)
2024-08-13-20.3%earningsSeeking AlphaVirpax Pharmaceuticals GAAP EPS of -$1.75
2024-08-13-20.3%legalSEC EDGARVRPX 8-K: 2.02 and (SEC Filing)
2024-07-29-18.4%newsSeeking AlphaVirpax Pharmaceuticals files to sell common stock, warrants
2024-12-13+16.9%legalSEC EDGARVRPX 8-K: 5.02 and (SEC Filing)
2022-11-09-16.4%earningsSeeking AlphaVirpax Pharmaceuticals GAAP EPS of -$0.65 misses by $0.14
2022-11-09-16.4%legalSEC EDGARVRPX 8-K: 2.02, 7.01 (SEC Filing)
2024-05-02-14.0%legalSEC EDGARVRPX 8-K: 5.02 and (SEC Filing)
2023-01-31+13.5%M&ASeeking AlphaVirpax engages New England Investors to explore license deal in China for nasal spray pain drug
2021-08-18+13.1%newsInvestorPlaceVRPX Stock: What Investors Are Saying About Virpax Pharma as Shares Continue to Fly - InvestorPlace
2024-07-26-11.8%legalSEC EDGARVRPX 8-K: 8.01 and (SEC Filing)
2023-11-15-11.5%earningsSeeking AlphaVirpax Pharmaceuticals GAAP EPS of -$0.51
2024-11-20-11.4%legalSEC EDGARVRPX 8-K: 5.02 and (SEC Filing)
2022-01-21-11.3%newsSeeking AlphaVirpax selects Altasciences to conduct trial of Epoladerm for chronic pain
2024-07-30-10.7%legalSEC EDGARVRPX 8-K: 3.01, 5.02, 5.07 (SEC Filing)
2024-05-13-10.7%legalSEC EDGARVRPX 8-K: 2.02 and (SEC Filing)
2024-07-15+10.2%legalSEC EDGARVRPX 8-K: 8.01 (SEC Filing)
2023-11-17-9.4%newsSeeking AlphaVirpax Pharmaceuticals gets non-compliance notice from Nasdaq
2023-11-17-9.4%executiveSeeking AlphaVirpax Pharmaceuticals CEO and Chairman resigns on ongoing litigation
2023-11-17-9.4%legalSEC EDGARVRPX 8-K: 5.02, 7.01 (SEC Filing)
2024-11-15+9.3%legalSEC EDGARVRPX 8-K: 1.01, 7.01 (SEC Filing)
2023-12-07-8.6%legalSEC EDGARVRPX 8-K: 5.02 and (SEC Filing)
2023-03-28-8.4%legalSEC EDGARVRPX 8-K: 5.02 and (SEC Filing)
2024-07-24-7.3%newsSeeking AlphaVirpax regains compliance with Nasdaq minimum bid price
2023-02-17-7.3%legalSEC EDGARVRPX 8-K: 8.01 (SEC Filing)
2023-06-20-7.3%executiveSeeking AlphaVirpax Pharmaceuticals appoints Vinay Shah as CFO
2024-04-18+7.1%newsSeeking AlphaVirpax Pharmaceuticals files to sell common stock and warrants
2022-05-05-7.1%newsSeeking AlphaVirpax teams up with US Army Institute to develop pain therapy Probudur
2024-02-27-6.6%newsSeeking AlphaScilex and Sorrento settle with Virpax and its founder Anthony Mack
2024-04-30-6.4%legalSEC EDGARVRPX 8-K: 8.01 and (SEC Filing)
2022-06-27+6.4%legalSEC EDGARVRPX 8-K: 8.01 and (SEC Filing)
2024-10-09-6.3%legalSEC EDGARVRPX 8-K: 3.01, 5.02 (SEC Filing)
2024-10-03-6.0%legalSEC EDGARVRPX 8-K: 5.02 (SEC Filing)
2024-10-03-6.0%legalSEC EDGARVRPX 8-K: 1.01 and (SEC Filing)
2023-11-16-5.9%legalSEC EDGARVRPX 8-K: 2.02 and (SEC Filing)
2024-12-30-5.8%legalSEC EDGARVRPX 8-K: 5.02 and (SEC Filing)
2022-03-15+5.5%legalSEC EDGARVRPX 8-K: 7.01, 8.01 (SEC Filing)
2021-08-10-4.8%legalSEC EDGARVRPX 8-K: 2.02, 7.01 (SEC Filing)
2025-01-07-4.3%legalSEC EDGARVRPX 8-K: 8.01 and (SEC Filing)
2025-02-06-4.3%legalSEC EDGARVRPX 8-K: 5.02 and (SEC Filing)
2021-12-08-4.3%newsSeeking AlphaVirpax reports results of toxicology and pharmacokinetic study for Epoladerm
2021-07-30+4.2%legalSEC EDGARVRPX 8-K: 5.02 and (SEC Filing)
2024-12-18-3.7%legalSEC EDGARVRPX 8-K: 5.02 and (SEC Filing)
2024-05-17-3.6%legalSEC EDGARVRPX 8-K: 1.01, 8.01 (SEC Filing)
2023-09-05-3.5%newsSeeking AlphaVirpax slips as court rules in favor of Scilex and Sorrento
2023-09-05-3.5%legalSEC EDGARVRPX 8-K: 7.01, 8.01 (SEC Filing)
2025-01-30-3.4%legalSEC EDGARVRPX 8-K: 1.01, 7.01 (SEC Filing)
2022-05-16-3.1%earningsSeeking AlphaVirpax Pharmaceuticals GAAP EPS of -$0.44
2022-05-16-3.1%legalSEC EDGARVRPX 8-K: 2.02, 7.01 (SEC Filing)
2022-10-31+3.1%analystZacks Investment ResearchWhat is the current Price Target and Forecast for Virpax Pharmaceuticals (VRPX) - Zacks Investment Research
2022-07-05+3.1%newsSeeking AlphaVirpax pursues over-the-counter medical device pathway for nasal spray AnQlar
2024-09-17-3.1%legalSEC EDGARVRPX 8-K: 5.02 (SEC Filing)
2023-06-07-2.9%legalSEC EDGARVRPX 8-K: 5.02, 5.03 (SEC Filing)
2023-12-29-2.8%newsSeeking AlphaVirpax Pharmaceuticals shareholders okay reverse stock split
2022-08-15-2.5%earningsSeeking AlphaVirpax Pharmaceuticals GAAP EPS of -$0.50 misses by $0.06
2022-08-15-2.5%legalSEC EDGARVRPX 8-K: 2.02, 7.01 (SEC Filing)
2023-08-14+2.3%earningsSeeking AlphaVirpax Pharmaceuticals GAAP EPS of -$0.27
2023-08-14+2.3%legalSEC EDGARVRPX 8-K: 2.02 and (SEC Filing)
2022-03-31-2.2%earningsSeeking AlphaVirpax Pharmaceuticals GAAP EPS of -$1.81
2022-03-31-2.2%legalSEC EDGARVRPX 8-K: 2.02, 7.01 (SEC Filing)
2023-06-21-1.9%legalSEC EDGARVRPX 8-K: 5.02, 7.01 (SEC Filing)
2021-05-18-1.8%legalSEC EDGARVRPX 8-K: 2.02, 7.01 (SEC Filing)
2024-03-26-1.6%earningsSeeking AlphaVirpax Pharmaceuticals GAAP EPS of -$12.97 misses by $4.77
2024-03-26-1.6%legalSEC EDGARVRPX 8-K: 2.02 and (SEC Filing)
2024-09-25-1.5%legalSEC EDGARVRPX 8-K: 4.01, 5.02 (SEC Filing)
2023-03-22+1.4%earningsSeeking AlphaVirpax Pharmaceuticals GAAP EPS of -$1.85 beats by $0.41
2023-03-22+1.4%legalSEC EDGARVRPX 8-K: 2.02 and (SEC Filing)
2023-03-30+1.3%newsCoinCodexVirpax Pharmaceuticals, Inc. (VRPX) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
2023-10-02-1.1%executiveSeeking AlphaGerald Bruce appointed CEO of Novvae Pharmaceuticals
2024-03-18-1.0%legalSEC EDGARVRPX 8-K: 3.01, 8.01 (SEC Filing)
2024-11-26-1.0%legalSEC EDGARVRPX 8-K: 8.01 and (SEC Filing)
2022-07-25-0.8%legalSEC EDGARVRPX 8-K: 5.02, 5.07 (SEC Filing)
2025-02-04-0.8%legalSEC EDGARVRPX 8-K: 5.02 and (SEC Filing)
2023-08-16+0.4%legalSEC EDGARVRPX 8-K: 5.02 and (SEC Filing)
2021-11-15+0.3%earningsSeeking AlphaVirpax Pharmaceuticals reports Q3 results
2021-11-15+0.3%legalSEC EDGARVRPX 8-K: 2.02, 7.01 (SEC Filing)
2023-05-12+0.1%earningsSeeking AlphaVirpax Pharmaceuticals GAAP EPS of -$0.13 beats by $0.17
2023-05-12+0.1%legalSEC EDGARVRPX 8-K: 2.02, 7.01 (SEC Filing)
2023-05-12+0.1%newsBusiness WireVirpax Pharmaceuticals Reports 2023 First Quarter Results and Recent Developments - Business Wire
tickerdossier.comtickerdossier.substack.com